|
|
Post by harryx1 on Feb 27, 2019 12:01:17 GMT -5
|
|
|
|
Post by sportsrancho on Feb 27, 2019 12:19:57 GMT -5
Awesome!!
|
|
|
|
Post by harryx1 on Feb 27, 2019 12:23:16 GMT -5
|
|
|
|
Post by akemp3000 on Feb 27, 2019 12:32:00 GMT -5
This is certainly one of the best health news video clips. I hope this is shared with many others. I plan on doing so. Thanks Harry!
|
|
|
|
Post by celo on Feb 27, 2019 13:04:28 GMT -5
Nice to see a television spot done by a newscaster who has diabetes. Really knows what she's talking about.
|
|
|
|
Post by sellhighdrinklow on Feb 28, 2019 14:33:47 GMT -5
"Mannkind is Hoping to have Afrezza approved for kids ages 8-12 within the next year or so". Is this more bad information or are 13-17 year olds considered adults
and able to have Afrezza prescribed now?
|
|
|
|
Post by mannmade on Feb 28, 2019 15:51:50 GMT -5
Looking to get approval for both.
|
|
|
|
Post by boca1girl on Feb 28, 2019 16:03:38 GMT -5
"Mannkind is Hoping to have Afrezza approved for kids ages 8-12 within the next year or so". Is this more bad information or are 13-17 year olds considered adults and able to have Afrezza prescribed now? This isn’t the first video coverage that quoted the ages wrong for pediatric trials. It’s 4-17. |
|
|
|
Post by joeypotsandpans on Feb 28, 2019 16:40:06 GMT -5
Harry you're truly relentless and I'm grateful of your consistently making others aware, the fact that you reached out to her with the FB post, I mean who does that...Harry that's who!!! = Relentless!! You're the best my friend 😉👍🏻
|
|
|
|
Post by Omega on Feb 28, 2019 21:53:34 GMT -5
Cohort 1 (Completed) was 13-17 year olds
Cohort 2 is 8-12 Year olds
|
|
|
|
Post by boca1girl on Mar 1, 2019 6:03:25 GMT -5
Cohort 1 (Completed) was 13-17 year olds Cohort 2 is 8-12 Year olds Does this mean that there is a Cohort 3 for 4-7 year olds? Is it intended to be approved for ages 4-17 when pediatric trials are complete? |
|
|
|
Post by mnholdem on Mar 1, 2019 6:47:33 GMT -5
Yes. The FDA wants 4-17 years of age in the trial. By having 3 cohorts MannKind is protecting results from the older groups. With the youngest cohort, the device itself may affect results. Even 4 year old patients are smart and coachable.
|
|
